Kolexia
Baumgaertner Isabelle
Oncologie médicale
Cabinet libéral
La Seyne-sur-Mer, France
115 Activités
11 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Adénocarcinome Métastase tumorale Tumeurs du foie Tumeurs du côlon Tumeurs du rectum Déficit en dihydropyrimidine déshydrogénase Tumeurs du pancréas Cholangiocarcinome

Industries

B3TSI
39 collaboration(s)
Dernière en 2023
A+A
38 collaboration(s)
Dernière en 2023
WorldOne
11 collaboration(s)
Dernière en 2020
M3 Global Research Ltd
9 collaboration(s)
Dernière en 2021

Dernières activités

Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol.
BMC cancer   12 octobre 2023
POCHI: Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
Cancer du Rectum Total Neoadjuvant Treatment "TNT ... - Facebook
Facebook   14 juillet 2023
Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.
European journal of cancer (Oxford, England : 1990)   07 juin 2023
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.
Journal of gastrointestinal oncology   10 avril 2023
Cancéro, uro, endocrino, dermato… Des experts, des PU-PH, qui sont les ...
What'up doc le Mag   27 mars 2023
TEDOPAM: A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Plus FOLFIRI, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM-D17-01 PRODIGE 63 Study)
Essai Clinique (Ose Immunotherapeutics)   24 février 2023
A randomized, non-comparative, phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo) or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): First interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY.
2022 ASCO Annual Meeting I   02 juin 2022
Mars Bleu 2022 cancer colorectal. Quelqu’un de ma famille a un cancer colorecta lQue dois-je faire?
Youtube @ Henri Mondor   31 mai 2022
FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   21 mai 2022